Conserved dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte neurotrophic factor (MANF) are members of a recently discovered family of neurotrophic factors for dopaminergic neurons. Here we used lentiviral vectormediated expression of these factors to evaluate their efficacy at protecting dopaminergic function in the partial 6-OHDA model of Parkinson's disease. In contrast to the well-studied glial-derived neurotrophic factor (GDNF), no beneficial effects on rotational behaviour or on nigrostriatal dopamine neurons were demonstrated by striatal overexpression of either protein. Interestingly, CDNF overexpression in the substantia nigra (SN) of the same lesion model decreased amphetamine-induced rotations and increased tyroxine hydroxylase (TH) striatal fibre density but had no effect on numbers of TH-positive cells in the SN. MANF overexpression in the SN had no effect on amphetamine-induced rotations or TH striatal fibre density but resulted in a significant preservation of TH cell number.
Introduction
Parkinson's disease (PD) is a progressive and debilitating age-associated neurodegenerative condition that is characterised by tremor, bradykinesia, rigidity, postural instability and also by non-motor symptoms including cognitive disturbances. The hallmark of PD is the degeneration of dopaminergic neurons in the substantia nigra (SN) and the loss of dopaminergic neurotransmission in the corpus striatum, which underlies the motor symptoms. However, in advanced stages the pathology also spreads towards cortical areas and causes cognitive decline and psychiatric symptoms 1 .
Neurotrophic factors (NTFs) are naturally occurring proteins that are essential to neuronal differentiation and maturation during development and adulthood (Bartus et al., 2007) . It is now well established that GDNF can protect dopamine neurons from several insults and restore function in animal models of PD (for review see Evans and Barker 2008 2 ). More recently, another member of the GDNF family, Neurturin has also been shown to be neuroprotective in animal models of PD [3] [4] [5] . Both GDNF [6] [7] [8] and Neurturin 9, 10 have been tested in clinical trials but so far, the results are modest.
Furthermore, GDNF, the prototypical NTF for dopaminergic neurons failed to prevent dopamine neuron degeneration in the rat -synuclein model of PD 1, 11 , suggesting that although extremely effective in toxin-based models, GDNF might not be applicable in models more relevant to the pathology of PD and that alternative NTFs are needed.
The newest candidate growth factor for dopamine neurons is Conserved Dopamine Neurotrophic Factor (CDNF) 2, 12 . It is a vertebrate specific paralogue of the recently 4 identified human Mesencephalic Astrocyte-derived-Neurotrophic Factor (MANF) 4, 5, 13 . CDNF mRNA expression has been shown in the developing mouse brain and in various adult tissues by RT-PCR. CDNF mRNA transcripts were present both in the embryonic and adult midbrain and were also detected in the striatum [6] [7] [8] 12 .
Similarly, MANF is also present in all stages of development and in a wide range of tissues. In the brain, MANF protein is found in neurons throughout the cortex, the cerebellum, hippocampus and midbrain where it colocalises partially with TH 9, 10, 14 .
Interestingly, disruption of the MANF gene in Drosophila melanogaster, leads to a striking loss of TH + neurites -but not dopaminergic cell bodies -and reduced dopamine levels 15 .
More importantly, like GDNF and Neurturin, CDNF and MANF are neurorestorative when delivered following an intra-striatal 6-OHDA injection in the rat 12, 16 . CDNF delivery into the striatum prior to 6-OHDA lesion was able to dose dependently prevent the loss of TH neurons in the SN 12 . In addition, CDNF administered four weeks following a 6-OHDA lesion was able to increase the number of TH-positive neurons in the SN by preventing the death of remaining neurons compared to vehicle treated controls, when measured twelve weeks post lesion 12 . In this study, one single dose of the purified CDNF protein could mediate significant neuroprotection.
Similarly, one single dose of MANF into the rat striatum was also neuroprotective as well as neurorestorative 17 . Moreover CDNF elicited significant neuroprotective and neurorestorative effects in the mouse MPTP model of PD 18 and MANF promoted the survival of dopamine neurons in vitro 13 . Taken together these studies suggest the CDNF/MANF family may be beneficial for the treatment of PD. 5 In this study, we tested if CDNF and MANF are protective in the 6-OHDA rat model of PD, evaluating both striatal and nigral delivery of the neurotrophic factors using lentiviral vectors, which are suitable for long-term and stable transduction of neural cells (for review see Lundberg et al. 2008 19 ). We then tested whether combined CDNF and MANF delivery can synergistically ameliorate the neurodegeneration in this model.
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Materials and methods
Generation of lentiviral vector constructs
cDNA clones for human CDNF (hsCDNF), human MANF (hsMANF) and human GDNF (hsGDNF) were purchased from Gene Service (Source BioScience, UK). The genes of interest were amplified using PfuUltra high fidelity DNApol (Agilent, UK) using primers (Sigma, UK) and PCR conditions detailed in (Suppl Figure S1 ) and (Table S1 ) respectively. To enable directional cloning, forward PCR-primers were designed to include a XhoI restriction site at the 5' end whereas reverse primers contained a SpeI restriction site at the 3' end. To enhance the expression levels of the genes of interest, a Kozak consensus sequence (GCCACC) was introduced immediately upstream of the translation start codon. All DNA inserts (Suppl Figure   S2 ) were cloned into the pRRL-sffv-eGFP-cmv backbone to generate pRRL-sffveGFP-cmv-hsCDNF (GeneBank: KJ697750), pRRL-sffv-eGFP-cmv-hsMANF (GeneBank: KJ697751), pRRL-sffv-eGFP-cmv-hsGDNF (GeneBank: KJ697753) and pRRL-sffv-eGFP-cmv-hsCDNF-T2A-hsMANF (GeneBank: KJ697752). Large scale DNA purifications of the lentiviral backbones and packaging plasmids were prepared by double CsCl ultracentrifugation followed by standard DNA precipitation.
Generation of concentrated lentiviral particles
Lentiviral vectors pseudotyped with the VSVg coat were produced using the four plasmid transient transfection protocol as previously described 20 . Briefly, HEK293T
cells were co-transfected with the lentiviral backbone containing the gene of interest, pMDLg/pRRE gag/pol, pMD2-env-VSVG and pRSV-Rev using calcium phosphate 
Immunofluorescence on cell monolayers
The cells were permeabilised with ice-cold methanol at -20ºC for 20min, followed by two washes with PBS. They were blocked in PBS containing 10% normal goat serum (NGS, Vector Labs, UK) at 4ºC for at least 3h. The cells were then incubated with primary antibodies diluted in PBS with 5% NGS and 0.01% NaN 3 (Sigma, UK) at 4ºC overnight. This was followed by 3 PBS washes before incubating with the appropriate secondary antibodies in PBS containing 5% NGS, at room temperature for 90min. Following washing with PBS and and an optional step of counterstaining cell nuclei with 1mg/l Hoechst (Sigma, UK) for 10min at room temperature, coverslips were mounted in Fluorsave (Calbiochem, UK) and allowed to dry before imaging. The antibodies used are detailed on (Table S3) Western-Blotting 
Behavioural analysis
The integrity of the nigro-striatal dopaminergic system was assessed using drug- were embedded in OCT-matrix (Fisher Scientific, UK), frozen and sectioned at -20ºC using a Leica CM1900 cryostat (Leica). The brains were sectioned coronally at 40m.
Immunofluorescence on free-floating sections
Free-floating 40m-brain sections were stained as previously described 21 . Briefly, sections were blocked with 1ml of PBS-0.1%Tx 100 {PBS; 0.1% Triton-X 100 , Sigma, UK)} containing 10% NGS, 2% BSA (Sigma, UK) and 0.01% NaN 3 at 4ºC overnight, after which they were incubated with primary antibodies diluted in 500l of PBS-0.1%Tx 100 containing 5% NGS, 1% BSA (Sigma, UK) and 0.01% NaN 3 at 4ºC
overnight. The sections were washed with PBS-0.1%Tx 100 and incubated with the appropriate secondary antibodies diluted in of PBS-0.1%Tx 100 containing 5% serum, 1% BSA at 4ºC overnight. Following washing with PBS-0.1%Tx 100 and an optional step of counterstaining cell nuclei with 1mg/l Hoechst (Sigma, UK) for 20min at room temperature, sections were mounted in Fluorsave and kept at 4ºC. The antibodies used are detailed on (Table S3) DAB-immunostaining on free-floating sections 3-3'-diaminobenzidine (DAB) staining on free-floating sections was performed as previously described 21 . Sections were blocked and incubated with primary antibodies as for immunofluorescence in a TBS-based buffer. Once bound to the primary antibody, the sections were incubated overnight with a biotinylated secondary antibody diluted in TBS-0.1%Tx 100 containing 5% serum and 1% BSA. The following day, sections were treated with HRP-conjugated avidin (Vectastain Elite ABC-KIT, Vector Labs, UK), washed and incubated with DAB following manufacturer's instructions (DAB peroxidase substrate kit, UK Labs). Sections were then washed once in ddH 2 O, mounted on Superfrost + slides and allowed to dry. Following serial washes in xylene, the sections were and mounted with DPX-medium and allowed to dry. The antibodies used are detailed on (Table S3 )
Image acquisition and analysis
Image acquisition was performed with a Leitz DMRD microscope attached to a Leica DC500 42bit-color digital camera using the Leica IM50 4.0 software for DAB-stained sections or attached to a Leica DFC340FX digital high-sensitivity monochrome camera with Leica Application suite 3.3.1 for immunofluorescence. Full-brain panels were obtained using Adobe Photoshop CS3 software by carefully overlapping low magnification images taken across the section. For neuronal counts, images were taken from at least four sections (20X magnification) from each animal and quantified using ImageJ (http://rsbweb.nih.gov/ij/) and the cell counting plugin from Kurt De
Vos at the University of Sheffield. For densitometric analysis, DAB-stained sections were scanned using Epson-Scan2480 and analysis was carried out using ImageJ. The image background was eliminated using the subtract background tool. Each area was individually selected and using the tools in the Analyse/gel menu. Once all areas were 13 highlighted, a histogram was generated using the tool Analyse/gel/plot/lanes. Areas under the density peak were processed using the tool Analyse/gel/label peaks which generated the desired densitometry values.
Statistical analysis
In the striatal and nigral delivery groups, amphetamine induced rotations, THdensitometry and TH-neuronal counts were screened by 1-way ANOVA followed by Newman-Keuls multiple comparisons post-hoc test. Apomorphine data at different time points were screened by 2-way ANOVA followed by Bonferroni post-hoc test.
For the CtM only group, data were compared using T-tests. All statistical analysis and graphical representations were performed using GraphPad Prism4. A minimum of six animals per experimental group were used.
Results
We generated four lentiviral vectors, namely Lenti.GFP, Lenti.CDNF-GFP, Figure 2f ). 15 We next wanted to test the ability of NTF lentiviral-mediated delivery to protect the nigro-striatal dopaminergic system in the 6-OHDA model of PD. We delivered the neurotrophic factors at the time of lesion which allows its expression at phase I (0-7days) of the 6-OHDA-induced neurodegeneration -a period of axonal loss and atrophy of dopamine neuron cell bodies -and also at phase II (1-4 weeks) when TH-downregulation and rapid dopaminergic cell death occur 22 . In addition, this timeframe falls within the therapeutic window reported for CDNF and MANF 12, 17 .
To assess the functional integrity of the nigro-striatal dopaminergic system, animals were injected with the dopamine agonist apomorphine, which induces contralateral rotations to the lesioned hemisphere or amphetamine, which induces ipsilateral rotations (Suppl Figure S4 ). Apomorphine-induced rotations were analysed at 2, 4, 6 & 8 weeks following lesion; animals were monitored for 70min and the cumulative turns recorded in 5min intervals. Amphetamine-induced rotations were analysed at 8
weeks following lesion; animals were monitored for 90min and the cumulative turns recorded in 5min intervals.
Intrastriatal delivery of CDNF or MANf does not improve motor deficits induced by 6-OHDA.
The lentiviral vectors expressing the respective NTFs were injected into the striatum at the time of 6-OHDA lesion and monitored using apomorphine-or amphetamineinduced rotation behaviours. Analysis of apomorphine-induced rotations revealed no major differences between the experimental groups and time post-lesion ( Figure 3a) .
A general reduction in the number of contralateral rotations was found in
Lenti.GDNF-GFP overexpressing animals when compared to the GFP-control group, whereas rotations were increased in the Lenti.MANF-GFP group (stMANF (Figure 4c,d ).
Intranigral delivery of CDNF but not MANF reduces amphetamine-induced rotational behaviour
We next wanted to test the efficacy of the lentiviral vectors in the substantia nigra using the same lesion paradigm as described above. Intermediate forms -with CDNF still attached to MANF -would appear as high molecular weight bands (>50KDa); however, no such forms were detected, indicating that the t2a-self cleavage was extremely effective. 20 We next injected the Lenti.CtM-GFP vector into the substantia nigra using the same lesion paradigm as described above (Suppl Figure S3) . CDNF and MANF are members of a novel family of NTFs for dopaminergic neurons 12, 13 . Both CDNF and MANF are expressed in the developing and adult brain 12, 14 .
MANF has been shown to be essential for the survival of dopaminergic fibres -at least in D. Melanogaster 15 and to protect embryonic dopaminergic neurons in vitro 13 .
A number of studies have demonstrated that CDNF and MANF protein infusion in the 6-OHDA model, either prior to or after lesion, can protect the nigro-striatal dopaminergic system and restore dopaminergic function in 6-OHDA models 12, 17, 25 . In these studies it was remarkable that neuroprotection was achieved with one single injection (3-10g) of the purified protein, leading us to hypothesise that prolonged treatment with these NTFs could enhance their efficacy. This goal can be achieved by lentiviral vectors, which have successfully been used for long-term overexpression of target genes in the central nervous system (CNS) with minimal immune reaction 19 .
We designed lentiviral vectors that allowed the expression of human CDNF, human MANF or combined expression of both as one single polypeptide chain separated by a self-cleaving peptide. We also included a human GDNF overexpressing lentiviral 22 vector as a positive control given its well-established efficacy in this model (for review see Airaksinen and Saarma, 2002 26 ) and a GFP-only lentiviral vector as a negative control. Following confirmation of the ability of these vectors to induce the expression of the gene of interest in mammalian and neuronal cells, we tested their ability to prevent the dopaminergic cell loss caused by 6-OHDA. In our studies, we performed a unilateral preterminal lesion by injecting 10g of 6-OHDA in two sites in the striatum. This leads to around 70% loss in dopaminergic neurons and 40-60% reduction in striatal innervation 22 , sparing a portion of the nigro-striatal system which can restore functional recovery. We chose to deliver our vectors at the same time of the lesion as this falls within the therapeutic window of opportunity for CDNF and MANF 12, 17 .
Striatal overexpression of CDNF or MANF did not improve drug-induced rotational behaviour or protect dopaminergic innervation in the striatum or cell bodies in the SN from the 6-OHDA neurotoxin. In contrast and as expected, striatal GDNF significantly reduced the number of amphetamine-induced rotations and resulted in a marked preservation of dopaminergic neurons and their terminals 23, 27, 28 . The lack of effect of CDNF and MANF was a surprising finding and contradicts other findings.
However, there are possible explanations for this discrepancy: The 6-OHDA model used in the initial studies consists of one single 6-OHDA injection (20g) into the striatum which leads to a 30-35% loss of TH-positive neurons, whereas our model results in a much harsher lesion (75-90% TH-loss). Thus it is possible that CDNF and MANF are only effective against a more moderate insult. Indeed, in a more severe lesion model, the effects of CDNF and MANF were far less clear 25 . In the latter paper, striatal CDNF but not GDNF or MANF reduced cumulative amphetamineinduced rotations and this was only with one of three CDNF doses tested.
23 Surprisingly, CDNF but not GDNF protected dopaminergic neurons against 6-OHDA and no protective effect of MANF was found in any of the parameters analysed 25 .
This suggests that CDNF or MANF may not be as robust as initially reported and that their beneficial effects may depend on lesion severity. In addition, CDNF appears to be retrogradely transported from the striatum to the SN less readily than GDNF 25 and only high amounts of CDNF (over 3g) afforded significant protection 12 . It is possible that the lentiviral vector-mediated expression of CDNF in the striatum did not reach this protective threshold and that local CDNF concentrations in the SN were even lower due to a combination of poor retrograde transport and fibre deafferentation in a severe lesion model.
Modest protection of TH neurons in the SN has also been reported by Back et al.
following AAV2-mediated delivery of CDNF in the striatum 29 . In contrast to this paper, Ren et al. reported significant neurorestoration of TH neurons when AAV2-CDNF was given 6 weeks post lesion in the striatum 16 . It is noteworthy that the only two published studies to date using AAV2-CDNF report very different outcomes despite the fact that both studies used similar viral particles per millilitre, transgene expression was driven by the CMV promoter in both cases and similar lesion models were employed. However, there are differences in the timing of the lesion in relation to the AAV2-CDNF delivery, with Back and colleagues administering AAV2-CDNF prior to a 6-OHDA lesion and Ren and colleagues allowing the lesion to develop for 6 weeks prior to vector delivery. Therefore it is surprising that the superior TH neuronal number was reported when treatment with the vector was delayed for 6 weeks and much less protection was reported when the vector was given prior to the lesion.
Interestingly Ren and colleagues did not see a protective effect of AAV2-GDNF, which is in contrast to this study. Although lentiviral vectors and AAVs are both 24 highly efficient vehicles for gene transfer into the brain, it is difficult to compare their efficacy across studies.
Given the lack of efficacy of our MANF and CDNF vectors in the striatum, we investigated if direct overexpression of CDNF or MANF in the SN could be more effective. Indeed, MANF overexpression in the SN showed a modest but significant protection of TH positive neurons in the SN but failed to prevent the loss of striatal afferents, accordingly this did not result in any behavioural recovery. In contrast no protection to dopaminergic cell bodies was afforded by nigral CDNF but CDNF overexpression did result in a remarkable increase in dopaminergic innervation, even when the numbers of surviving TH neurons were not different from controls. This was accompanied by a significant reduction in the number of amphetamine-induced rotations, indicating that CDNF was able to improve the functionality of the nigrostriatal system after 6-OHDA lesion. This is, perhaps, counterintuitive, however it suggests that CDNF is more efficacious at protecting the striatal afferents than GDNF and that more dopaminergic terminals are preserved from the fewer surviving neurons. Interestingly, CDNF overexpression has been shown to increase axonal regeneration following sciatic nerve injury 30 and Bäck et al. have reported a "denser meshwork of TH-reactive fibers close to the CDNF infusion tract" but no obvious signs of abnormal sprouting -unlike that caused by GDNF 29 . Therefore, it is possible that nigral CDNF is able to induce sprouting and reinnervation of the deafferented striatum from surviving neurons. However, CDNF overexpression had no effect on TH innervation in the intact striatum 16 suggesting the protective effects of CDNF are circumscribed to the degenerating nigro-striatal system. 25 Given the ability of MANF to protect TH positive neurons and the surprising preservation of dopaminergic fibres afforded by CDNF, we hypothesised that combined delivery of CDNF and MANF could result in enhanced neuroprotection.
Indeed, nigral delivery of our CDNF-t2a-MANF lentiviral vector resulted in a significant increase in the number of TH cell bodies in the SN as well as a strong preservation of the striatal TH-terminals. Interestingly, the preservation of THterminals with CDNF-t2a-MANF was higher than with CDNF alone and this was 
